Femoropopliteal Artery Stent Thrombosis

Original Title: Femoropopliteal Artery Stent Thrombosis. Report from the Excellence in Peripheral Artery Disease Registry. Reference: Subhash Banerjee et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002730.

 

There is limited information on peripheral stent thrombosis and involved factors.

This study analyzed 604 stent procedures in femoropopliteal territory form the multicenter registry “Excellence in Peripheral Artery Disease”.

Stent thrombosis occurred in 26 of the 604 patients (4.3%) at median 6 month follow up post procedure.

Stent thrombosis was more frequent in men and when the lesion originally treated was a chronic total occlusion.

There were no differences in stent thrombosis between drug-coated and bare metal stents (4.4% vs 3.4%; p=0.55) but there were differences between self-expandable covered stents vs. conventional bare metal stents (10.6% vs 3.4%; p=0.02).

Thrombosis was associated to a much higher risk of adverse events over the same treated limb (HR, 4.99; CI 95% 2.31 to 10.77; p<0.001).

Multivariable analysis showed that chronic total occlusion (OR, 3.46; IC 95% 0.98 a 12.20; p=0.05) and in-stent restenosis (OR, 5.30; IC 95%, 1.83 a 15.32; p=0.002) were independently associated with stent thrombosis.

Conclusion
This multicenter registry of peripheral intervention showed that femoropopliteal stent thrombosis is 4.3% and is associated to the treatment of chronic total occlusions and restenosis of previous stents. Thrombosis is strongly associated to adverse events in this lower limb.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....